Jan. 21 at 12:13 PM
Cantor reiterated
$MNPR Overweight/
$109
$AZN
Cantor said in its note:
Monopar tells us they met with the FDA last year and that the company remains on track to file an NDA in
1H26. Recall, there is also a Patient-Focused Drug Development (PFDD) Meeting taking place next week, 1/29. This is the core priority for the company this year. If you've ever met CEO Dr. Chandler Robinson, then you'll know there is nothing more important to him than getting this therapy to patients. While he understands that investors are curious to hear the specifics behind these meetings, it's very important for him to maintain the high integrity of the review process. Thus, we didn't hear any color. But our own take is that things must be progressing well considering filing plans remain on track.
